An evaluation of inhibin and activin as early markers of pre-eclampsia and fetal growth restriction.

抑制素和激活素作为先兆子痫和胎儿生长受限的早期标志物的评估。

• 批准号: nhmrc : 124507
• 负责人: Prof Euan Wallace
• 金额: $ 6.46万
• 依托单位: Monash University
• 依托单位国家: 澳大利亚
• 项目类别: NHMRC Project Grants
• 财政年份: 2000
• 资助国家: 澳大利亚
• 起止时间: 2000-01-01 至 2002-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/an-evaluation-inhibin-growth-restriction/98609
• 关键词: evaluation; inhibin; activin; early; markers

Pre-eclampsia and fetal growth problems are among the major causes of maternal and perinatal death in Australia. One of the most pressing difficulties in the management of these conditions is our present inability to accurately predict those women who are destined to have one or other of these serious complications. Unfortunately, this means that the conditions are often detected late with little or no time to offer effective treatments. This project builds on exciting preliminary evidence that suggests that a simple blood test from the mother in early pregnancy may be able to identify the women who will subsequently develop high blood pressure in late pregnancy, or the babies that will suffer impaired growth before delivery. In the future, such knowledge might then allow these women to receive more effective care, thereby improving their chance of a successful pregnancy. The project will also define the best time in pregnancy to perform the blood test and, if successful, could alter the very way women are currently looked after during their pregnancy.

先兆子痫和胎儿生长问题是澳大利亚孕产妇和围产期死亡的主要原因之一。管理这些疾病的最紧迫的困难之一是我们目前无法准确预测那些注定要患有这些严重并发症的妇女。不幸的是，这意味着这些疾病往往被发现得很晚，几乎没有时间提供有效的治疗。该项目建立在令人兴奋的初步证据的基础上，这些证据表明，在怀孕早期对母亲进行简单的血液测试可能能够识别随后在怀孕后期患上高血压的妇女，或者在分娩前发育受损的婴儿。将来，这些知识可能会使这些妇女得到更有效的护理，从而提高她们成功怀孕的机会。该项目还将确定怀孕期间进行血液测试的最佳时间，如果成功，可能会改变目前妇女在怀孕期间的照顾方式。